{"id":535581,"date":"2021-09-08T08:33:34","date_gmt":"2021-09-08T12:33:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\/"},"modified":"2021-09-08T08:33:34","modified_gmt":"2021-09-08T12:33:34","slug":"minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\/","title":{"rendered":"Minerva Neurosciences Announces Appointment of  Dr. Ramana Kuchibhatla as Senior Vice President  and Head of Research &amp; Development"},"content":{"rendered":"<h2>\nDr. Jay Saoud, Head of Research &amp; Development, to retire from his current role and transition to an advisory role in which he will continue to support the preparation and planned submission of a New Drug Application (NDA) for Minerva\u2019s lead program, roluperidone<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>WALTHAM, Mass., Sept.  08, 2021  (GLOBE NEWSWIRE) &#8212; Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced Dr. Jay Saoud\u2019s retirement and transition to an advisory role and Dr. Ramana Kuchibhatla\u2019s appointment as Senior Vice President and Head of Research &amp; Development, both effective September 16, 2021.\u00a0Dr. Kuchibhatla will report directly to\u00a0Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva.<\/p>\n<p>\u201cI would like to thank Jay for the invaluable skill and leadership which have enabled Minerva to take roluperidone from early stage clinical development through phase 3 and towards preparation for a potential NDA submission,\u201d said Dr. Luthringer. \u201cI look forward to continuing to work with him in his new role.\u201d<\/p>\n<p>\u201cI am excited to welcome Ramana to the Minerva leadership team,\u201d added Dr. Luthringer. \u201cHe is a key addition to our team as we continue to develop roluperidone for the treatment of negative symptoms of schizophrenia. His track record in leading the development of CNS drugs that address unmet needs, combined with his impressive IND to NDA experience, will strongly support our forthcoming interactions with the FDA.\u201d<\/p>\n<p>\u201cI have been impressed by the clinical data package that the team at Minerva has compiled to support the NDA for roluperidone for the treatment of negative symptoms in schizophrenia, an indication for which there are currently no approved treatment options in the US,\u201d said Dr. Kuchibhatla. \u201cI look forward to finalizing the preparation of the NDA and interacting with the FDA in the coming months. I believe roluperidone has the potential to address a significant unmet need in the treatment of schizophrenia.\u201d<\/p>\n<p>Dr. Kuchibhatla brings to Minerva more than 35 years of drug development, regulatory, biostatistical and operations leadership experience in the life sciences and biotech industries. He joins Minerva from PRA Health Sciences Inc, a subsidiary of ICON, where he served as Executive Director of Global Drug Development. Prior to PRA, Dr. Kuchibhatla was Senior Vice President, Clinical Development &amp; Biostatistics at Melior Pharmaceuticals Inc. \u00a0He previously founded QED Pharmaceutical Services, a contract research organization specializing in clinical and data services, and served as Senior Director of Clinical R&amp;D at Targacept Inc, a company specializing in the development of drugs for neuropsychiatric indications. He has held several posts of increasing responsibility within the neurology and psychiatry group at GlaxoSmithKline Inc, where he was involved in the filing of NDAs for Zyban &amp; Lamictal.<\/p>\n<p>Dr. Kuchibhatla earned his M.A. and Ph.D. at the University of Iowa.<\/p>\n<p>\n        <strong>About Minerva Neurosciences<\/strong>\n      <\/p>\n<p>Minerva\u2019s portfolio of compounds includes: roluperidone (MIN-101), in clinical development for treatment of negative symptoms of schizophrenia, and MIN-301, in pre-clinical development for Parkinson\u2019s disease. Minerva\u2019s common stock is listed on the NASDAQ Global Market under the symbol \u201cNERV.\u201d\u00a0For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=25bvqLHysHL_F6rP2GJ3VPOjKXOsbHo7RuaPxxzhFuwX-sFApjaBPnD-VOsAyzmUfSfK27kC_8Fh7T4IGaWmCZKp21dud_O8fq_HPdsQGUyVXTbvSnHABGgXIvMS3Oj0\" rel=\"nofollow noopener\" target=\"_blank\">www.minervaneurosciences.com<\/a>.<\/p>\n<p>\n        <strong><br \/>\n          <em>Forward-Looking Safe Harbor Statement<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <em>This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts, reflect management\u2019s expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the timing and scope of future clinical trials and results of clinical trials with roluperidone (MIN-101); the clinical and therapeutic potential of this compound; the likelihood of successful clinical trials, regulatory review, commercialization, and future sales of and potential royalty stream from seltorexant; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies; our ability to successfully develop and commercialize our therapeutic products; the sufficiency of our current cash position to fund our operations; and management\u2019s ability to successfully achieve its goals. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether roluperidone will advance further in the clinical trials process and whether and when, if at all, it will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether any of our therapeutic products or seltorexant will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; management\u2019s ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions. These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption \u201cRisk Factors\u201d in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended\u00a0June 30, 2021, filed with the\u00a0Securities and Exchange Commission on August 2, 2021. Copies of reports filed with the\u00a0SEC\u00a0are posted on our website at <\/em><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=25bvqLHysHL_F6rP2GJ3VPOjKXOsbHo7RuaPxxzhFuxZi8ZjOlQ5jiN5yzH0sFkcJxDgGR6ls-dxlHSIQif6xIPv2qoac-MWMvFUZB3CyAUKhSQhLbjX0Gbj5LyDbrRD\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <em>www.minervaneurosciences.com<\/em><br \/>\n        <\/a><br \/>\n        <em>. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.<\/em>\n      <\/p>\n<p align=\"left\">\n        <strong>Contact<\/strong>:<br \/>William B. Boni<br \/>VP, Investor Relations\/<br \/>Corp. Communications<br \/>Minerva Neurosciences, Inc.<br \/>(617) 600-7376<\/p>\n<p>\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDk0NyM0MzkxMjk5IzIwMDcyNDU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NzA2M2U1ZjUtZmZlNS00NjQwLTg2NmMtMDY3ZDJhZTkxZGE2LTEwMTg4MTg=\/tiny\/Minerva-Neurosciences-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dr. Jay Saoud, Head of Research &amp; Development, to retire from his current role and transition to an advisory role in which he will continue to support the preparation and planned submission of a New Drug Application (NDA) for Minerva\u2019s lead program, roluperidone WALTHAM, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) &#8212; Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced Dr. Jay Saoud\u2019s retirement and transition to an advisory role and Dr. Ramana Kuchibhatla\u2019s appointment as Senior Vice President and Head of Research &amp; Development, both effective September 16, 2021.\u00a0Dr. Kuchibhatla will report directly to\u00a0Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Minerva Neurosciences Announces Appointment of  Dr. Ramana Kuchibhatla as Senior Vice President  and Head of Research &amp; Development&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-535581","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research &amp; Development - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research &amp; Development - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Dr. Jay Saoud, Head of Research &amp; Development, to retire from his current role and transition to an advisory role in which he will continue to support the preparation and planned submission of a New Drug Application (NDA) for Minerva\u2019s lead program, roluperidone WALTHAM, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) &#8212; Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced Dr. Jay Saoud\u2019s retirement and transition to an advisory role and Dr. Ramana Kuchibhatla\u2019s appointment as Senior Vice President and Head of Research &amp; Development, both effective September 16, 2021.\u00a0Dr. Kuchibhatla will report directly to\u00a0Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva. &hellip; Continue reading &quot;Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research &amp; Development&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-08T12:33:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDk0NyM0MzkxMjk5IzIwMDcyNDU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research &amp; Development\",\"datePublished\":\"2021-09-08T12:33:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\\\/\"},\"wordCount\":907,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMDk0NyM0MzkxMjk5IzIwMDcyNDU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\\\/\",\"name\":\"Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research &amp; Development - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMDk0NyM0MzkxMjk5IzIwMDcyNDU=\",\"datePublished\":\"2021-09-08T12:33:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMDk0NyM0MzkxMjk5IzIwMDcyNDU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMDk0NyM0MzkxMjk5IzIwMDcyNDU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research &amp; Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research &amp; Development - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\/","og_locale":"en_US","og_type":"article","og_title":"Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research &amp; Development - Market Newsdesk","og_description":"Dr. Jay Saoud, Head of Research &amp; Development, to retire from his current role and transition to an advisory role in which he will continue to support the preparation and planned submission of a New Drug Application (NDA) for Minerva\u2019s lead program, roluperidone WALTHAM, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) &#8212; Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced Dr. Jay Saoud\u2019s retirement and transition to an advisory role and Dr. Ramana Kuchibhatla\u2019s appointment as Senior Vice President and Head of Research &amp; Development, both effective September 16, 2021.\u00a0Dr. Kuchibhatla will report directly to\u00a0Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva. &hellip; Continue reading \"Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research &amp; Development\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-08T12:33:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDk0NyM0MzkxMjk5IzIwMDcyNDU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research &amp; Development","datePublished":"2021-09-08T12:33:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\/"},"wordCount":907,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDk0NyM0MzkxMjk5IzIwMDcyNDU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\/","name":"Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research &amp; Development - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDk0NyM0MzkxMjk5IzIwMDcyNDU=","datePublished":"2021-09-08T12:33:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDk0NyM0MzkxMjk5IzIwMDcyNDU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDk0NyM0MzkxMjk5IzIwMDcyNDU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research &amp; Development"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/535581","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=535581"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/535581\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=535581"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=535581"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=535581"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}